MODERN METHODS OF OBESITY TREATMENT
Keywords:
obesity, liraglutide, weight loss, cardiometabolic parameters, GLP-1 agonistAbstract
Relevance: Obesity is a significant global health issue requiring effective treatment methods. This study evaluates the impact of liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, on non-diabetic obese patients. Purpose: To assess the effects of liraglutide on weight loss and cardiometabolic parameters. Materials and Methods: The study involved 20 patients receiving liraglutide for 12 weeks. Key indicators included weight loss and changes in cardiometabolic parameters. Results: Liraglutide-treated patients showed a weight reduction of 5.8%, with fasting glucose decreasing by 8.4%. Triglycerides decreased by 12%, and systolic blood pressure dropped by 5 mm Hg. Conclusion: Liraglutide is an effective and safe drug for weight loss and improving cardiometabolic health.
References
Пресс-релиз ВОЗ от 1 марта 2024 года.
ПП-4891 «О дополнительных мерах по обеспечению общественного здоровья путем дальнейшего повышения эффективности работ по медицинской профилактике».
Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А., Трошина Е.А., Мазурина Н.В., Ершова Е.В., Комшилова К.А., Андреева Е.Н., Анциферов М.Б., Бирюкова Е.В., Бордан Н.С., Вагапова Г.Р., Волкова А.Р., Волкова Н.И., Волынкина А.П., Дзгоева Ф.Х., Киселева Т.П., Неймарк А.Е., Романтсова Т.И., Руяткина Л.А., Суплотова Л.А., Халимов Ю.Ш., Яшков Ю.И. Ожирение. Consilium Medicum. 2021 Июл; 23(4):311–325. doi: 10.26442/20751753.2021.4.200832.
Трошина Е.А., Ершова Е.В. Фармакотерапия ожирения: что нового? Проблемы Эндокринологии. 2018 Сен; 64(4):270–276. doi: 10.14341/probl9315.3. Garvey W.T. Clinical definition of overweight and obesity. In: Gonzalez-Campoy J, Hurley D, Garvey W, editors. Bariatric Endocrinology. Switzerland: Springer Cham; 2019. doi: 10.1007/978-3-319-95655-8_7.
Garvey W.T. Clinical definition of overweight and obesity. In: Gonzalez-Campoy J, Hurley D, Garvey W, editors. Bariatric Endocrinology. Switzerland: Springer Cham; 2019. doi: 10.1007/978-3-319-95655-8_7.
Greenspan F.S., Gardner D.G. Greenspan’s Basic and Clinical Endocrinology. New York: McGraw-Hill Medical; 2011.
NIH Obesity Research Task Force. Strategic plan for NIH obesity research. Bethesda, MD: National Institutes of Health; 2019.
Pi-Sunyer X., Astrup A., Fujioka K., Greenway F., Halpern A., Krempf M., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. SCALE Obesity and Prediabetes. N Engl J Med. 2015; 373:11–22. doi: 10.1056/NEJMoa1411892.
Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F.E., Nauck M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. LEADER trial. N Engl J Med. 2016; 375:311–322. doi: 10.1056/NEJMoa1603827.
Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., Jódar E., Leiter L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. SUSTAIN-6 trial. N Engl J Med. 2016; 375:1834–1844. doi: 10.1056/NEJMoa1607141.
